-transparent.png){kind=logo}
In a double-blind multicentre study the efficacy and safety of a single-dose treatment with pefloxacin (800 mg) was compared with a five-day treatment regimen of 960 mg co-trimoxazole twice daily in the therapy of acute uncomplicated cystitis in women. In order to maintain blindness, patients in the pefloxacin group received placebo to complement the full number of tablets. Nine centres were involved; 155 patients received pefloxacin and 161 patients received co-trimoxazole. Of these, 140 patients treated with pefloxacin and 145 with co-trimoxazole were considered valid for efficacy and safety analysis. At the first follow-up, after seven to ten days, 97.1% of the pefloxacin group and 95.2% of the co-trimoxazole group were bacteriologically cured. At the second follow-up visit, after 28 to 42 days, the urine culture was negative in 95.0% of the pefloxacin group and 90.3% of the co-trimoxazole group. A single dose of 800 mg pefloxacin was demonstrated to be as safe and at least as effective as a five-day regimen of co-trimoxazole in the treatment of uncomplicated cystitis.
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
May 1985,
The New Zealand medical journal,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
August 1981,
International journal of clinical pharmacology, therapy, and toxicology,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
May 1983,
The Practitioner,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
March 1981,
Annales de la Societe belge de medecine tropicale,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
January 1982,
Schweizerische medizinische Wochenschrift,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
October 1990,
The Journal of antimicrobial chemotherapy,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
December 1980,
Australian and New Zealand journal of medicine,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
January 1995,
Drugs,
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
February 1995,
Presse medicale (Paris, France : 1983),
E E Petersen, and
F Wingen, and
K L Fairchild, and
A Halfhide, and
A Hendrischk, and
M Links, and
M Schad, and
H R Scholz, and
N Schürmann, and
S Siegmann
October 1980,
The New Zealand medical journal,
